Abstract:Objective::In 2015, the Chinese Pancreatic Association of the Chinese Society of Surgery of the Chinese Medical Association launched a national multicenter online system for registration of surgical treatment of pancreatic cancer in China, called China Pancreas Data Center (CPDC). With continued effort, the CPDC has developed over time. Herein, we report the general results of the CPDC from January 2016 to January 2020 to present the real-world situation of surgical treatment of pancreatic cancer in China.Methods::The data of the CPDC from January 2016 to January 2020 were retrieved and analyzed in this real-world study, including the data on patient demographics, comorbidities, diagnostic modalities, neoadjuvant treatment, surgical procedures, postoperative complications and treatment, pathological examinations, postoperative adjuvant treatment, survival, and risk factors.Results::A total of 13,595 cases from 70 centers in 28 provinces were retrieved for analysis. This study reported the largest cohort of patients who underwent surgical treatment for pancreatic cancer in China to date. More cases were derived from the Eastern regions, among which Shanghai, Beijing, and Zhejiang ranked in the top three. The peak age of the patients ranged from 60 to 69 years. The ratio of males to females was 1.5:1. Overall, 64.3% of the tumors were located in the head and neck of the pancreas, and 35.7% in the body and tail of the pancreas. Of the patients, 23.0% underwent positron-emission tomography-computed tomography, 21.6% underwent endoscopic ultrasound, and 4.8% underwent preoperative biopsy. Two percent of the patients underwent neoadjuvant treatment, while 68.9% underwent R0 surgical resection (margin free of tumor cells). Of the latter, 78.6% of the operations were open procedures, 12.6% were laparoscopic procedures, 2.9% were robotic procedures, and 3.7% were converted to open procedures. The in-hospital mortality rate after surgery was 0.4%. The incidence of grade 2 and grade 3 postoperative pancreatic fistulas was 25.5% and 2.5%, respectively. The incidence of complications based on the Clavien-Dindo classification was 17.9% of grade II, 4.3% of grade IIIa, 1% of grade IIIb, and 0.6% of grade IV. Of the patients, 28.9% underwent postoperative adjuvant chemotherapy. The 1-year, 2-year, and 3-year overall survival of these patients were 77%, 51%, and 38%, respectively. In the 8542 patients who underwent R0 resection, the 1-year, 2-year, and 3-year overall survival and disease-free survival were 77% , 54%, and 43%, and 68%, 49%, and 41%, respectively. The factors related to the prognosis of these patients were also identified after uni-and multi-variate analyses.Conclusion::The surgical quality, safety, and long-term survival of the patients in CPDC are similar to those of international high-volume pancreatic centers. However, neoadjuvant and postoperative adjuvant chemotherapy should be improved.

Diagnosis and treatment of pancreatoblastoma in China.

Diagnosis and treatment of pancreatic islet cell tumor:a report of 35 cases

Management of Primary Squamous Cell Carcinoma of the Pancreas: A Case Report.

Diagnosis, treatment, and prognosis of adult pancreatoblastoma

Pancreatoblastoma: A Case Report and Literature Review

[Analysis of Treatment Modalities and Prognosis of Patients with Gallbladder Cancer in China from 2010 to 2017].

Childhood pancreatoblastoma: Clinical features and immunohistochemistry analysis

Clinical Insights and Outcomes Compared to Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatoblastoma in previously pancreatic pseudocysts in a 14-year-old female: a case report

Adult pancreatoblastoma: clinical features and Imaging findings

AB086. P058. Current Status of Pancreatic Cystic Neoplasm: Diagnosis and Treatment a Multi-Institution Retrospective Study in China

[The Diagnosis and Treatment of Pancreatic Neuroendocrine Neoplasms].

Diagnosis and treatment of anaplastic carcinoma of the pancreas

Real-world Study of Surgical Treatment of Pancreatic Cancer in China: Annual Report of China Pancreas Data Center (2016-2020)

Guidelines for the Diagnosis and Treatment of Pancreatic Cancer in China (2021)

Diagnosis and Treatment of 40 Cases of Pancreatic Cystic Neoplasms

Fine Needle Aspiration Cytology of Pancreatoblastoma in Adult/Adolescent Patients, One With Histology Mimicking NUT Carcinoma

Clinical Analysis of Acinar Cell Carcinoma of the Pancreas: A Single-Center Experience of 45 Consecutive Cases.

Neuroendocrine tumors of pancreas: treatment and survival analysis

The Real-World Study of the Clinical Characteristics, Diagnosis, and Treatment of Advanced Pancreatic Cancer in China

Cancer Statistics: Current Diagnosis and Treatment of Pancreatic Cancer in Shanghai, China.